Disease · MONDO_0004785

blepharitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. blepharitis. Diseases, record MONDO_0004785. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0004785

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: blepharitis; Open Targets
Open Targets ID: MONDO_0004785; Open Targets
Other names: eyelid inflammation, inflammation of eyelid; Open Targets
Disease Ontology: DOID:9423; Disease Ontology
MeSH: D001762; MeSH
NCI Thesaurus: C112183; NCI Thesaurus
Highest stage of its drugs: Approval, for 6 of its 23 drugs, from DailyMed and PMDA; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZITHROMYCIN	CHEMBL529	Small molecule	Approval	PMDA	12	11	11	Drugs and targets
GATIFLOXACIN	CHEMBL31	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
GENTAMICIN SULFATE	CHEMBL6067484	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
LEVOFLOXACIN	CHEMBL5315124	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
MOXIFLOXACIN HYDROCHLORIDE	CHEMBL1200735	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
VANCOMYCIN HYDROCHLORIDE	CHEMBL1200628	Small molecule	Approval	PMDA	1	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	5	5	5	Drugs and targets
LOTILANER	CHEMBL3707310	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
IVERMECTIN	CHEMBL6067487		Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TOBRAMYCIN	CHEMBL1747	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 1/2	https://conductscience.org/library/genes/3554	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Phase 2	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	1	Matrix metalloproteinase 7 inhibitor	Phase 2	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	1	Matrix metalloproteinase 8 inhibitor	Phase 2	https://conductscience.org/library/genes/4317	Drugs and targets

Trials28

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01543490	Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects	Phase 3	558	2021-03-23	Active, Symptomatic Blepharitis	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT04475432	Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis	Phase 2/3	421	2023-12-21	Blepharitis	LOTILANER	Its record names the disease	ClinicalTrials.gov
NCT04784091	Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis	Phase 3	412	2023-12-21	Blepharitis	LOTILANER	Its record names the disease	ClinicalTrials.gov
NCT04675242	Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis	Phase 2	224	2022-12-14	Blepharitis	FLUTICASONE PROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT01783860	Oral Azithromycin Versus Doxycycline in Posterior Blepharitis	Phase 2	100	2014-02-12	Posterior Blepharitis	AZITHROMYCIN, DOXYCYCLINE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01089608	Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis	Phase 2	93	2014-11-04	Blepharitis	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov
NCT00681109	Topical IL-1-Ra for Treatment of Posterior Blepharitis	Phase 1/2	75	2012-11-27	Posterior Blepharitis	ANAKINRA	Open Targets' reading of its record	ClinicalTrials.gov
NCT00560703	Treatment of Patients With Blepharitis and Facial Rosacea	Phase 2	70	2012-01-11	Blepharitis, Meibomianitis, Dry Eye	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT03926026	Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis	Phase 2	36	2023-01-19	Blepharitis	FLUTICASONE PROPIONATE	Its record names the disease	ClinicalTrials.gov
NCT01408082	Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis	Phase 3	917		Blepharitis	AZITHROMYCIN, DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 28

See all 28 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
ISV-305 vs Vehicle: deaths from any cause	0 of 367	0 of 188	555	NCT01543490	Trial comparisons
ISV-305 vs Vehicle: serious adverse events	4 of 367	0 of 188	555	NCT01543490	Trial comparisons
Active vs Control: deaths from any cause	0 of 212	0 of 209	421	NCT04475432	Trial comparisons
Active vs Control: serious adverse events	3 of 212	1 of 209	421	NCT04475432	Trial comparisons
Active vs Control: deaths from any cause	0 of 203	0 of 209	412	NCT04784091	Trial comparisons
Active vs Control: serious adverse events	4 of 203	3 of 209	412	NCT04784091	Trial comparisons
NCX 4251 vs Placebo: Treatment-emergent Adverse Events	12 of 111	17 of 113	224	NCT04675242	Trial comparisons
NCX 4251 vs Placebo: deaths from any cause	0 of 111	0 of 113	224	NCT04675242	Trial comparisons
NCX 4251 vs Placebo: serious adverse events	0 of 111	0 of 113	224	NCT04675242	Trial comparisons
Doxycycline vs Oral Azithromycin: serious adverse events	12 of 50	3 of 50	100	NCT01783860	Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37285925	DERIVED	1	PubMed
35965392	DERIVED	1	PubMed
29325546	DERIVED	1	PubMed
25138765	DERIVED	1	PubMed
23599118	DERIVED	1	PubMed
21138337	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0004785

GET https://conductscience.org/api/diseases/v1/MONDO_0004785/drugs?page=2

API reference For AI assistants